After the FDA warning and removal of rosiglitazone from the VA National Formulary, glucose control may have declined among those discontinuing rosiglitazone without receiving replacement medication.
Roslyn A. Stone, PhD
Advertisement
Articles by Roslyn A. Stone, PhD
Advertisement
Latest Updated Articles
- Implementation of an Inpatient Management and Discharge Strategy for Patients With Community-acquired Pneumonia
Published: August 1st 2005 | Updated:
- FDA Warning and Removal of Rosiglitazone From VA National Formulary
Published: September 19th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Biktarvy Improves ART Persistence for People With HIV and Mental Health Disorders
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5
